OBEJECTIVE: To investigate whether the expression of uncoupling proteins (UCP2 and UCP3) was affected by a very low calorie diet (VLCD) and growth hormone (GH) treatment for 4 weeks. DESIGN: A randomized, placebo-controlled intervention study of VLCD with or without concomitant GH-treatment. SUBJECTS: Seventeen obese women (body mass index, BMI 42.1 AE 1.4 kgam 2 (range 31.8 ± 54.5 kgam 2 )) treated with VLCD for 4 weeks and randomized to concomitant placebo treatment (n 9) or GH treatment (n 8). MEASUREMENTS: Fat mass and lean body mass were measured by dual-energy X-ray absorptiometry. Energy expenditure (EE) was measured by indirect calorimetry. UCP2 and UCP3 mRNA were measured in adipose tissue and skeletal muscle biopsies before VLCD and after VLCD AE GH-treatment by reverse transcription polymerase chain reaction (RT-PCR). RESULTS: VLCD treatment resulted in a mean weight loss of 5.23 kg AE 0.8 (P`0.01), a 4.1% decrease in EE (P`0.05) and a 24% decrease in UCP3 mRNA in adipose tissue (P`0.03), whereas adipose tissue UCP2 mRNA and skeletal muscle UCP2 and UCP3 mRNA levels were unchanged. GH-treatment had no effects on EE, changes in body weight or UCP mRNA level. In multiple regression analysis the change in EE caused by VLCD was signi®cantly correlated with changes in adipose tissue UCP2 mRNA (r 0.66, P`0.02) and a tendency towards a signi®cant association with the change in adipose tissue UCP3 mRNA (r 0.45, P 0.09), but not with change in body weight, skeletal muscle UCP2 or UCP3 mRNA levels. CONCLUSION: VLCD for 4 weeks decreased UCP3 mRNA expression in human adipose tissue, whereas GH-treatment had no effect on UCP expression. Multiple regression analysis demonstrated that changes in adipose tissue UCP2 and probably UCP3 mRNA were correlated with the change in EE. These ®ndings indicate that UCPs in adipose tissue in very obese individuals might play a role for the reduction in EE observed during energy restriction.
Introduction
Uncoupling proteins (UCPs) are a subgroup of mitochondrial carrier proteins which uncouple electron transport from ATP synthesis and are thought to be implicated in regulation of energy expenditure. Three UCP isoforms have been identi®ed: UCP1, which was the ®rst to be cloned, 1 is thought to be exclusively expressed in brown adipose tissue that is present only in very small amounts in adult humans; 2,3 UCP2 expression is observed in a wide variety of tissues in both rodents and humans; 4 UCP3 is highly expressed in skeletal muscle and only very weakly expressed in adipose tissue. 5 As UCP2 and UCP3 are expressed in adult humans, these proteins could play important roles in regulation of energy expenditure and may contribute to obesity and type 2 diabetes. 6, 7 The expression of UCP2 and UCP3 mRNA has been reported in rodents to be regulated by thyroid hormone and fastingarefeeding, 8 but only very few studies have reported on the regulation of these UCPs in humans. Millet et al 9 demonstrated that fasting (1045 kJaday) for 5 days decreased energy expenditure but increased the expression of UCP2 in skeletal muscle and in adipose tissue. UCP3 mRNA levels were also induced in skeletal muscle in response to fasting. 9 In addition, a positive correlation between adipose tissue UCP2 mRNA level and BMI was detected. In contrast, Oberko¯er 10 reported that obese and lean individuals had similar UCP2 mRNA in subcutaneous adipose tissue, but the obese had reduced UCP2 mRNA in intra-abdominal adipose tissue compared with the lean and, ®nally, Schrauwen et al 11 described a correlation between skeletal muscle UCP3 mRNA expression and energy expenditure in Pima Indians. Thus, it is possible that UCPs might be involved in controlling body composition and energy expenditure in humans.
Generally, treatment of obesity involves some degree of energy restriction, and it is well known that energy restriction is followed by a reduction in resting metabolic rate (RMR). 12 Thus, it is interesting to study whether changes in RMR are related to changes in the expression of UCP2 and UCP3. Barbe et al 13 reported that a very low calorie diet (VLCD) is associated with unaltered UCP2 mRNA expression in adipose tissue after 25 days on VLCD; however, the UCPs in skeletal muscle were not investigated. As skeletal muscle is the most important tissue in controlling energy expenditure we found it of interest to investigate the effects of VLCD on UCP mRNA expression in skeletal muscle.
In addition, we and others have previously described growth hormone (GH) treatment of obese individuals (without any change in diet) promoting loss of adipose tissue 14, 15 and increasing whole body energy expenditure. 16 Others have suggested that a hypocaloric diet combined with GH-treatment is more effective in promoting loss of adipose tissue, 17, 18 whereas other studies did not ®nd any additive effect when combining VLCD and GH. 19 ± 21 In addition, we recently reported that GH-treatment of growth hormone de®cient (GHD) adults was associated with an increase in UCP3 mRNA expression in skeletal muscle as well as in adipose tissue. 22 Therefore, we studied the effects of VLCD and GH treatment on weight loss, the change in energy expenditure (EE) and the expression of UCP mRNA in adipose tissue and skeletal muscle, in order to determine whether GH treatment under these circumstances had any in¯uence on UCP mRNA expression.
Materials and methods

Subjects
Seventeen obese women (body mass index, BMI 42.1 AE 1.4 kgam 2 (range 31.8 ± 54.5 kgam 2 )) who were referred to the out-patient clinic at the hospital for weight reduction comprised the study group. Their body weight was stable for at least 2 months prior to the investigation. All were premenopausal and took no medication. Before inclusion a physical examination was found normal, and all had a normal oral glucose tolerance test.
Study design
The investigation was performed as a double-blind placebo-controlled study. All the obese women were treated with a very-low calorie diet (VLCD; BliLet, Nycomed DAK) of 3135 kJaday (containing 85 g protein, 73 g carbohydrate and 12 g fat) for 4 weeks. The women were randomized to either GH-treatment (n 8) or placebo-treatment (n 9) during the VLCD treatment. The dose of GH was given subcutaneously once daily in the evening and was gradually increased during the 4 weeks: 0.03 IUakg ideal body weight (IBW) in the ®rst week; 0.04 IUakg IBW in the second week; 0.06 IUakg IBW in week three, and 0.08 IUakg in week four. The total daily dose was, however, restricted so the maximal dose didn't exceed 6 IU. As shown in Table 1 , there were no differences at baseline between the placebo group and the GHtreated group in age, body composition or metabolic variables.
Body composition
Body composition was determined by dual-energy X-ray apsorptiometry (DEXA) scan using a Hologic QDR-1000W scanner as previously described. 23 The amounts of fat (FM) and lean body mass (LBM) were determined. LBM comprises both muscle tissue and nonmuscle fat-free tissue (including water-space).
Indirect calorimetry
Indirect calorimetry (Deltatract monitor, Datex Instrumentarium, Helsinki, Finland) was performed for 20 min in the morning after an overnight fast. 16 The patients were instructed not to engage in exercise in the days prior to the measurement. The initial 5 min of calorimetry at every phase were used for acclimatization and no data were collected during this process. Estimated rates of lipid and glucose oxidation and total energy expenditure (EE) were calculated after correction for protein oxidation, which was estimated after measurements of urinary excretion of urea. 24 Urine for determination of urea was collected from the beginning of the basal period to the end of the study.
Adipose tissue biopsies
An adipose tissue biopsy was obtained after an overnight fast as previously described from the subcu taneous abdominal region (periumbilically). 14 The biopsy was performed by needle aspiration (liposuction) after local anaesthesia with lidocaine. The adipose tissue was washed to remove blood, and frozen in liquid nitrogen for later RNA extraction. Biopsies were obtained before and after VLCD treatment AE GH. From one patient, adipose tissue biopsy was only obtained before the VLCD period. Effects of VLCD and GH on UCP mRNA SB Pedersen et al
Muscle biopsies
The skeletal muscle biopsy was taken from the m. vastus lateralis with a Bergstro Èm needle as previously described. 25 Under local anaesthesia (lidocaine), a small incision was made through the skin and muscle sheet approximately 15 cm above the knee. The muscle biopsy was quickly cleaned for blood and frozen in liquid nitrogen for later RNA extraction. Biopsies were obtained before and after VLCD treatmentAE GH from all patients.
Isolation of RNA
Total RNA was isolated from the biopsies using the TriZol reagent (Gibco BRL, Life Technologies, Roskilde, Denmark). RNA was quantitated by measuring absorbance at 260 and 280 nm and the ratio should be 1.8 or higher. Finally, the integrity of the RNA was checked by visual inspection of the two ribosomal RNAs 18S and 28S on an agarose gel.
Reverse transcription PCR (RT-PCR) assay for detection of UCP2 and UCP3 mRNA in adipose tissue and skeletal muscle
Reverse transcription was performed using random hexamer primers as described by the manufacturer (GeneAmp RNA PCR Kit from Perkin Elmer Cetus, Norwalk, CT) at 23 C for 10 min, 42 C for 60 min, and terminated by increasing the temperature to 95 C for 10 min. Then, PCR-mastermix containing the speci®c primers and AmpliTaq GOLD DNA polymerase was added.
In order to determine the linearity of DNA ampli®cation, preliminary experiments were performed for UCP2, UCP3 and b-actin in adipose tissue and skeletal muscle separately. A linear increase in PCR product was observed when using RNA ranging between 1 and 300 ng (data not shown), thus, all subsequent PCR reactions were performed using 25 ng RNA. A second set of PCR reactions using 25 ng RNA was designed to determine the appropriate number of cycles to be run. Once determined, these conditions we further optimized the protocol in order to perform semi-quantitative multiplex PCR with primer dropping. 26 Semi-quantitative multiplex PCR estimates the relative amount of message RNA to a known housekeeping gene (b-actin) as internal control to monitor the sample to sample variability of the RTstep as well as the PCR-step. However as the target message is present in much lower copy number than the housekeeping gene, we added the housekeeping primers after a few cycles of ampli®cation of the target DNA. By performing experiments, the number of necessary initial cycles before dropping the housekeeping primers was determined for UCP2 and UCP3 in both adipose tissue and skeletal muscle. For UCP2 in adipose tissue b-actin was dropped after eight cycles and the remaining 24 cycles were performed, and for UCP3 in adipose tissue, b-actin primers were dropped after 12 cycles, 24 cycles remaining. For UCP2 in skeletal muscle, b-actin primers were dropped after nine cycles, 24 remaining; and ®nally for UCP3 in skeletal muscle, b-actin was dropped after four cycles, 24 remaining.
A similar set-up was used for negative controls except that the reverse transcriptase was omitted and no PCR-products were detected under these conditions. The PCR-products were loaded on a 2% agarose gel, stained with ethidiumbromide, and analysed using the Bio-Rad Gel-Doc 1000 system where the ratio between the target PCR product and the b-actin PCR product was calculated. The coef®cient of variation (CV) for the UCPab-actin ratio was 12.4% (n 15).
The following primer pairs were used: UCP2 
C for 60 s ®nally the product was extended for 5 min at 72 C.
Statistical analysis
Data is given as mean AE s.e.m. and Student's paired ttest was used to compare before and after values. Oneway analysis of variance (ANOVA) followed by Duncan's post hoc analysis was used when performing multiple comparisons (P`0.05 was considered signi®cant). Finally, backward multiple regression analyses were performed. All analyses were performed with the SPSS statistical package.
Results
Effects of VLCD AE GH treatment for 4 weeks on body composition and energy expenditure
After VLCD (3135 kJaday) treatment for 4 weeks the subjects had lost around 5 kg of body weight (0.1 ± 12.0 kg); the losses of LBM and FM are shown in Table 1 . There were no differences between the placebo treated and the GH-treated subjects in the change in body weight, the LBM or FM (Table 1 ).
In the placebo-treated group the energy expenditure was signi®cantly reduced (72.03 AE 0.81 kcalakg LBMa24 h) after VLCD treatment for 4 weeks, whereas no signi®cant fall in EE was observed after VLCD in the GH-treated group (70.75 AE 1.37 kcalakg LBMa24 h (NS)). However, the decline in EE in the placebo-treated group and the GH-treated group was not signi®cantly different between the two groups (P 0.42, NS). We also calculated the residuals from the relationship between EE and FFM and
Effects of VLCD and GH on UCP mRNA SB Pedersen et al analysis showed that the residuals were similar in the placebo-treated group and the GH-treated group (residuals in placebo group 41.73AE 78.60 and in the GHgroup 37.09 AE 53.47 (P 0.539)), indicating that GH had no in¯uence on the EE after adjustment for the effects of LBM.
As expected the GH-treated group had a signi®-cantly higher IGF-1 level compared with the placebogroup after treatment for four weeks (P`0.001; Table 2 ).
Correlations at baseline between UCP mRNA, body composition, hormones, and energy expenditure At baseline the energy expenditure (kcala24 h) was correlated with LBM (r 0.67, P`0.003), FM (r 0.617, P`0.008) and total body weight (r 0.748, P`0.001). At baseline none of the UCP mRNAs in either fat or muscle tissue were signi®-cantly correlated with FM, LBM, BMI or energy expenditure (data not shown). In addition baseline values of FFA, FT3, FT4 or leptin were not correlated with any of the UCPs in either adipose tissue or skeletal muscle (data not shown).
Effects of VLCD and GH-treatment on UCP2 mRNA levels UCP2 mRNA levels in adipose tissue and skeletal muscle were unchanged after 4 weeks on VLCD (Figure 1) . Furthermore, GH along with VLCD had no in¯uence on the UCP2 expression ( Figure 1 ).
Effects of VLCD and GH-treatment on UCP3 mRNA levels
In adipose tissue the level of UCP3 mRNA was reduced by 24% (P`0.05) in the biopsy obtained after VLCD treatment for 4 weeks as compared with initial values (Figure 1) . The adipose tissue UCP3 mRNA level was reduced comparable with and without additional treatment with GH ( Figure 1) . In skeletal muscle UCP3 levels were not affected by VLCD or by GH-treatment (Figure 1 ). The relationships between the change in mRNA levels of UCP2 and UCP3 were also examined. Figure 2 shows the correlation between changes in UCP2 and UCP3 in skeletal muscle (r 0.503, P`0.05) and between the change in UCP3 mRNA in skeletal muscle and adipose tissue (r 0.534, P`0.05). The positive correlations between the changes in UCP2 and UCP3 in skeletal muscle might indicate that gene transcription of these genes may be controlled by common regulators, as also suggested by Bao et al. 6 Correlation analysis
Despite a mean change in body weight of 5 kg, some of the subjects lost 12 kg, whereas others lost only 0.1 kg during the 4 weeks of VLCD. Since GHtreatment had no effect on energy expenditure, body composition or UCP mRNA expression, the data from GH-treated and placebo-treated subjects were pooled in the following correlation analysis. In these very obese individuals there was a positive correlation between the changes in adipose tissue UCP2 mRNA and the fall in EE per kg LBM (r 0.523, P`0.04, n 16) (Table 3) or EE per kg body weight (r 0.56, P`0.05; Figure 3 ). Furthermore, there was a tendency for an association between percentage change in adipose tissue UCP3 mRNA levels and change in EE per kg LBM (r 0.464, P 0.07, n 16; Table 3 ). Multiple regression analysis using percentage change in EE as the dependent variable and percentage change in AT-UCP2, AT-UCP3, SM-UCP2, SM-UCP3 and change in body weight as independent variables, revealed that only percentage change in adipose tissue UCP2 mRNA was independently correlated with EE (0.66, P`0.02) when taking the other variables into account. Repeating the multiple regression analysis using the absolute values instead revealed similar results. The change in EE was correlated with change in adipose tissue UCP2 mRNA (r 0.52, P`0.05), but also the change in adipose Figure 2 Interrelationships between UCP2 and UCP3 mRNA levels in skeletal muscle (A) and UCP3 mRNA in skeletal muscle and adipose tissue (B). Data is given as change in the ratio UCP mRNAÂ100ab-actin mRNA (before ± after VLCD). Table 3 Pearsson's correlation coef®cient between change (before ± after VLCD) in UCPs in adipose tissue and skeletal muscle and change (before ± after VLCD) in EE, change in body composition, total T4 (TT4), and FFA Figure 3 Correlation between skeletal the change in adipose tissue UCP2 expression (UCP mRNAÂ100ab-actin mRNA (before ± after VLCD)) and the change in energy expenditure (EEakg body weighta24 h; before ± after VLCD).
Effects of VLCD and GH on UCP mRNA SB Pedersen et al tissue UCP3 mRNA tended to contribute independently to the variation in EE (r 0.45, P 0.09), whereas changes in body weight and changes in skeletal muscle UCP2 and UCP3 mRNA still had no independent effect on the association.
Discussion
VLCD treatment of obese subjects for 4 weeks reduced body weight by 4.5%, reduced fat mass by 4.3%, lean body mass by 0.9% and energy expenditure by 4.1%. In order to investigate whether the newly discovered UCP2 and UCP3 may be involved in the changes in energy expenditure, the expression of UCPs in both adipose tissue and skeletal muscle was determined before and after 4 weeks of a VLCD. At baseline, energy expenditure was closely correlated with FM and LBM but not with any of the UCPs. Furthermore no correlation between initial BMI and any UCP mRNA concentration in either skeletal muscle or adipose tissue was demonstrated, as also described by Esterbauer et al. 27 However, negative correlations between both UCP mRNA expression and BMI, 9, 11, 28 as well as positive correlations, 6,9 have previously been described. The reason for these divergent results is not clear, but the subjects in the present study were all morbidly obese with a mean BMI of 42.1AE 1.4 kgam 2 (range 31.8 ± 54.5 kgam 2 ) and this might in¯uence the possibility of detecting any association between BMI and UCP mRNA levels in the present study, compared with most of the other studies which included both obese and lean individuals.
Our results are in agreement with a recent study by Barbe et al 13 demonstrating that VLCD-treatment of obese individuals for 25 days did not in¯uence adipose tissue UCP2 expression. Furthermore, the present study extends these ®ndings by demonstrating that skeletal muscle UCP2 and UCP3 expression were unaffected, whereas adipose tissue UCP3 expression was signi®cantly reduced after VLCD treatment. From a previous study we have found that GH-treatment of obese individuals increased EE, 15 and recently we described that GH-treatment for 4 months of adult GHD patients was associated with an increased UCP3 mRNA expression in both adipose tissue and skeletal muscle. Accordingly we hypothesized that GH may increase the expression of UCPs during VLCD treatment of obese individuals; however, in the present study GH had no convincing effect on the reduction in EE seen in association with the pronounced hypocaloric diet. In addition, the UCPexpression in both adipose tissue and skeletal muscle were unaffected by GH treatment given concomitantly to VLCD. Whether this is due to the present experimental conditions or whether GH has no direct effect on UCP in muscle and adipose tissue is yet to be elucidated.
Multiple regression analysis revealed that the relative change in EE per kg LBM during VLCD treatment was correlated with the relative change in adipose tissue UCP2, whereas the change in body weight, or the change in SM-UCP2 or change in SM-UCP3 did not contribute to the variation in EE. Whether AT-UCP3 together with AT-UCP2 are involved in the change in energy expenditure cannot be solved by the present correlation analysis. Furthermore, since UCP2 is expressed at a much higher level than UCP3 in adipose tissue it seems questionable if UCP3 plays a major role for the energy expenditure in adipose tissue. Although the AT-UCP3 expression is rather low, as demonstrated by northern blot analysis, 29 we 22 as well as others 30 have been able to study the regulation in UCP3 expression in adipose tissue by using the very sensitive RT-PCR technique. How the expressions of the UCPs are regulated is yet to be elucidated. Different hormones are known to regulate the mRNA expression of UCP; leptin, thyroid hormones and b3-adrenergic agonists all seem capable of stimulating UCP mRNA expression in adipose tissue as well as in skeletal muscle in rodents. 29 During a hypocaloric diet the concentration of thyroid hormones 12 as well as serum leptin is reduced; however, we did not detect any correlation between the concentration of thyroid hormones or leptin and the UCP expression (Table 3) , arguing against a role for these hormones in controlling the UCP expression during VLCD treatment. Other studies have indicated that severe starvation stimulates skeletal muscle UCP mRNA expression, 29, 31 which is probably mediated through elevation of free fatty acids. 32 A recent study demonstrated that rodent skeletal muscle UCP3 mRNA level was regulated differentially in fasting as compared with an energy restricted diet. Fasting for one week increased UCP3 mRNA 5.6-folds, whereas a 50% energy restricted diet for one week resulted in an 81% reduction in skeletal muscle UCP3 mRNA. 33 In the present study no correlation between basal FFA and UCP expression was shown; however, after 4 weeks on VLCD there was a strong positive correlation between FFA and skeletal muscle UCP2 mRNA, and a correlation between the changes in FFA and the change in skeletal muscle UCP2 mRNA expression was found (r 0.76, P`0.001, Table 3 ). These ®nd-ings could indicate that FFA also in humans might be involved in the control of skeletal muscle UCP expression.
Whether the magnitude of catabolism or the length of the catabolic condition affects UCPs differentially in humans is unknown; however, the short term study by Miller et al 9 (using a more severe hypocaloric diet for 5 days) demonstrated an increase in UCP2 expression, whereas the two studies using VLCD for weeks (the present study and the study by Barbe et al 13 both demonstrated that adipose tissue UCP2 expression was unaffected by the diet, thus suggesting a complex modulation of UCP expression by food intake andaor length of catabolism. Our ®nding that the changes in Effects of VLCD and GH on UCP mRNA SB Pedersen et al UCP2 and UCP3 during a VLCD were interrelated supports a recent paper by Bao et al 6 suggesting that common factors might be involved in regulation of skeletal muscle UCP2 and UCP3 mRNA levels. Furthermore, our ®nding of a correlation between changes in adipose tissue UCP3 and skeletal muscle UCP3 extends this hypothesis and might suggest that UCP3 gene transcription in the two tissues could be controlled by common regulators during VLCD as well.
In conclusion, the change in EE observed during VLCD treatment for 4 weeks was closely correlated to the change in fat mass and lean body mass. However, in multiple regression analysis only the change in AT-UCP2 and possibly AT-UCP3 expression contributed independently to the variation in EE. Weight loss after VLCD was associated with signi®cant reduction in AT-UCP3 expression whereas concomitant GH-treatment had no signi®cant effect on UCP expression, loss of fat mass or EE. These ®ndings indicate that the level of energy restriction andaor the length of the diet period may have differential effects on the UCP mRNA expression, which might have important implications for the treatment of obesity.
